Overview
- Zydus Lifesciences posted consolidated net profit of Rs 1,042.1 crore, up 1.81% year on year, on revenue of Rs 6,864.5 crore, up 30.3%.
- North American sales for Zydus rose 16.4% as the company launched four additional products in the quarter.
- Zydus recorded a one-time impact of Rs 84.9 crore from India’s new labour codes, which contributed to a 17.2% sequential decline in net profit.
- Aurobindo Pharma reported Q3 net profit of about Rs 910 crore, up roughly 8% year on year, with revenue at approximately Rs 8,646 crore and a Rs 653.3 million labour‑code charge.
- Industry pressure from weak U.S. generic pricing persisted, with peers such as Cipla and Dr Reddy’s reporting softer U.S. sales this quarter.